

# PERFORMANCE EVALUATION OF ARTERIAL PRESSURE CARDIAC OUTPUT SYSTEMS AS COMPARED TO STANDARD THERMODILUTION AND OTHER ALTERNATIVE CARDIAC OUTPUT MEASUREMENTS

**Protocol Number: 2005-03**

**Revision C**

**Effective date: February 10, 2006**

Published: 21-08-2007

Last updated: 20-05-2024

The purpose of this study is to evaluate accuracy of Cardiac Output measurements by comparing the Cardiac Output calculated by Arterial Pressure based Cardiac Output (APCO) and by other well accepted indicator dilution techniques, as well by...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Will not start
<b>Health condition type</b>	Heart failures
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON29845

### Source

ToetsingOnline

### Brief title

MASTERMIND

## Condition

- Heart failures
- Cardiac therapeutic procedures

### Synonym

Measurement of the performance of the heart

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Edwards Lifesciences LLC

**Source(s) of monetary or material Support:** Edwards Lifesciences LLC

## Intervention

**Keyword:** Cardiac Output, FloTrac, Monitoring, Vigileo

## Outcome measures

### Primary outcome

Intermittent Cardiac Output (ICO)

Continuous Cardiac Output (CCO)

### Secondary outcome

Demographics, Reason for Hemodynamic monitoring, Pre-existing conditions, Heart rate, Arterial Pressure, systemic Vascular Resistance, Ease of Use, Adverse Events, Termination from the study, and Definition of competitive cardiac output technology.

## Study description

### Background summary

MASTERMIND

Performance Evaluation of Arterial Pressure Cardiac Output Systems as Compared

2 - PERFORMANCE EVALUATION OF ARTERIAL PRESSURE CARDIAC OUTPUT SYSTEMS AS COMPARED T ...  
27-05-2025

to Standard Thermodilution and other Alternative Cardiac Output Measurements.

Sponsor:

Edwards Lifesciences LLC

One Edwards Way

Irvine, CA 92614 USA

The FloTrac Sensor is a less invasive hemodynamic monitoring device that, when used with the Vigileo monitor, measures continuous cardiac output (CCO) through an arterial pressure line.

### **Study objective**

The purpose of this study is to evaluate accuracy of Cardiac Output measurements by comparing the Cardiac Output calculated by Arterial Pressure based Cardiac Output (APCO) and by other well accepted indicator dilution techniques, as well by competitive technology and devices (COCD).

### **Study design**

This is a prospective, paired sample comparison study that will be conducted at various sites located throughout Europe.

### **Study burden and risks**

No burden or risks considered associated with participation.  
This will be an observation study.

## **Contacts**

### **Public**

Edwards Lifesciences LLC

One Edwards Way

Irvine, CA 92614

USA

### **Scientific**

Edwards Lifesciences LLC

One Edwards Way

Irvine, CA 92614

USA

## **Trial sites**

### **Listed location countries**

Netherlands

## **Eligibility criteria**

### **Age**

Adults (18-64 years)

Elderly (65 years and older)

### **Inclusion criteria**

Patient must have an indwelling pulmonary artery catheter and either a radial or a femoral or other arterial catheter in order to participate in the study.

Patient will have the pulmonary artery catheter remain in-situ for a minimum of 8 hours after study initiation.

Patient is able to comply with the study procedure.

Patient, guardian or person authorized with power of attorney to give informed consent prior to placement of indwelling catheters according to applicable country specific law.

Patient must be 18 years old or older.

Ability to obtain an accurate subject height and weight prior to study start and as required during the study period.

### **Exclusion criteria**

Patients with contraindications for the placement of radial, femoral or other arterial cannulae.

Patients with aortic valve regurgitation

Patients being treated with an intraaortic balloon pump.

Patients less than 40 kg in weight.

Pronounced cardiac arrhythmia (such as bigeminy).

Female patients of childbearing potential with a known pregnancy.

Any contraindications for the type of COCD being evaluated.

The subject is currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the study endpoints.

(Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available are not considered investigational trials.)

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Will not start

Enrollment: 20

Type: Anticipated

## Ethics review

Approved WMO

Application type: First submission

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

### Register

CCMO

### ID

NL12988.058.06